Lyka Labs Q1 FY27: consolidated PAT doubles YoY to ₹2.05 Cr as revenue rises 28%
PAT +105.44% YoY · revenue +28.11% · margins expanding
₹42.31 Cr
+28.11% YoY
₹2.05 Cr
+105.44% YoY
4.79%
+1.8pp YoY
₹0.57
Lyka Labs' consolidated revenue for the quarter ended 30 June 2026 rose 28.1% YoY to ₹42.31 Cr from ₹33.03 Cr, while consolidated PAT more than doubled YoY to ₹2.05 Cr from ₹1.00 Cr — a print that also reverses the ₹8.07 Cr consolidated loss booked in the March-2026 quarter. PBT grew a more modest 44% YoY to ₹1.95 Cr; the extra lift to PAT came from a ₹0.10 Cr deferred-tax credit versus a ₹0.05 Cr tax charge a year ago, so the bottom-line gain overstates the operating improvement. NPM (PAT/total income) rose to 4.79% from 2.96% YoY, but OPM was essentially flat at 10.75% against 11.16% a year ago — cost ratios for materials, employee expense and other overheads moved only marginally — making this more a tax-and-base-effect story than a margin-expansion one. Standalone tracks closely (revenue ₹42.31 Cr, PAT ₹2.10 Cr, EPS ₹0.58 vs ₹0.22 YoY); the ₹0.05 Cr gap to consolidated PAT is the subsidiary Lyka BDR International's own quarterly loss.
Q1 FY-2027 vs prior quarters
On the same day, the board also approved 100% divestment of Lyka BDR International — a subsidiary that contributed 8% of FY26 consolidated income (₹10.55 Cr) and carries a negative net worth of ₹4.49 Cr — with sale terms, buyer and consideration still to be finalised and delegated to the Audit Committee. Separately, the NCLT-sanctioned merger of Lyka Export Limited into Lyka Labs (order dated 16 March 2026) is now reflected in restated prior-period figures under Ind AS 103. There is no formal management guidance on record for this company, and a web search for Q1 FY27 previews/estimates turned up no analyst or brokerage coverage for this micro-cap, so both vs-guidance and vs-street are unknown; the filing itself carries no separate management commentary beyond the standard board-outcome letter. The subsidiary sale terms and whether the deferred-tax credit that flattered this quarter's PAT persists are the two items likely to matter more to the trend than this quarter's headline number.
The stock went into the print at ₹74.83, up 27.9% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters.
What the summary numbers don't show
No exceptional items this quarter in either statement — prior quarter's ₹23.01 Cr standalone exceptional loss does not recur
W1
Terms, buyer and completion timeline of the Lyka BDR International divestment (100% stake, 8% of FY26 consolidated income) — to be disclosed once finalised
W2
Whether OPM (10.75% this quarter, down slightly from 11.16% YoY) holds or improves as cost ratios normalise post the Lyka Export merger restatement
W3
Whether the ₹0.10 Cr deferred-tax credit that boosted this quarter's PAT reverses to a charge in coming quarters
Converted from ₹ Lakhs to ₹ Crore. Consolidated PAT is the total (₹2.0466 Cr, before NCI); owners'-share PAT is ₹2.0652 Cr (NCI ₹-0.0186 Cr), which is the EPS base. No exceptional items this quarter in either statement; the prior quarter's ₹23.01 Cr exceptional loss appeared only in the standalone P&L (not consolidated), consistent with it being an intra-group write-down tied to subsidiary Lyka BDR International, now approved for divestment. Standalone and consolidated revenue are identical this quarter because the subsidiary reported nil revenue.